PET imaging for Treatment Response in Cancer

about

The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.

P2860

Q41425861-5A41623E-5838-427A-B739-FE095A9E4300

P2860

PET imaging for Treatment Response in Cancer

Item

http://www.wikidata.org/entity/Q37465205

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PET imaging for Treatment Response in Cancer

@en

PET imaging for Treatment Response in Cancer.

@nl

type

Item

label

PET imaging for Treatment Response in Cancer

@en

PET imaging for Treatment Response in Cancer.

@nl

prefLabel

PET imaging for Treatment Response in Cancer

@en

PET imaging for Treatment Response in Cancer.

@nl

P1476

PET imaging for Treatment Response in Cancer

@en

P2093

Janet F Eary

http://www.w3.org/2001/XMLSchema#string

P2860

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.

Usefulness of preoperative FDG-PET for detection of gastric cancer.

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls.

Evaluation of therapy for lymphoma.

Monitoring chemotherapy and radiotherapy of solid tumors.

P304

101-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CPET.2008.10.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40689106

http://www.w3.org/2001/XMLSchema#string

P698

20011618

http://www.w3.org/2001/XMLSchema#string

P932

2790286

http://www.w3.org/2001/XMLSchema#string

PET imaging for Treatment Response in Cancer

about

P2860

P2860

PET imaging for Treatment Response in Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932